SCHEMBL24364150

SCHEMBL24364150

Cc1cc(NC(=O)C(=O)O)cnc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 10/20 0.50
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
GPR35 Q9HC97 5/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30469637 1.00 PRMT5 (0.50) PRMT5NOS3NOS1NOS2GPR35
SCHEMBL29346064 0.87 PRMT5 (0.47) PRMT5NOS3NOS1NOS2KDM4E
SCHEMBL24365900 0.84 PRMT5 (0.46) PRMT5NOS3NOS1NOS2KDM4E
SCHEMBL30471174 0.83 PRMT5 (0.49) PRMT5GPR35WDR77
SCHEMBL24363962 0.83 PRMT5 (0.49) PRMT5GPR35WDR77
SCHEMBL25786654 0.83 PIK3CA (0.47) PRMT5NOS3NOS1NOS2KDM4E
SCHEMBL24363880 0.81 GABRP (0.41) PRMT5NOS3NOS1NOS2GPR35
SCHEMBL30469592 0.81 GABRP (0.41) PRMT5NOS3NOS1NOS2GPR35
SCHEMBL29477460 0.79 PRMT5 (0.44) PRMT5NOS3NOS1NOS2KDM4E
SCHEMBL24363787 0.78 GPR35 (0.50) GPR35ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023114507-A1 CRYSTALLINE FORM OF N-(6-AMINO-5-METHYLPYRIDIN-3-YL)-2-(BENZO[D]THIAZOL-5-YL)-5-METHYLPIPERIDIN-1-YL)-2-OXOACETAMIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-22 WO disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 PRMT5 347/4885NOS3 556/4885NOS1 619/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 PRMT5 347/4885NOS3 556/4885NOS1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.